Pharmaceuticals

Multiple Myeloma Drugs Market Insights Report: Opportunities and Drivers 2030

February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the multiple myeloma drugs market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Multiple Myeloma Drugs Market between 2026 and 2030?

The multiple myeloma drugs market has demonstrated robust expansion over recent years. It is projected to increase from $23.03 billion in 2025 to $24.4 billion in 2026, at a compound annual growth rate (CAGR) of 6.0%. This historical growth can be ascribed to factors such as the increasing occurrence of multiple myeloma, the approval of new immunomodulatory drugs, greater public awareness about plasma cell cancers, the advancement of proteasome inhibitors, and the expansion of hospital pharmacy networks.

The multiple myeloma drugs market is projected to experience substantial growth over the upcoming years, with its size anticipated to reach $31.61 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.7%. This expansion in the forecast period is primarily attributed to increased adoption of precision medicine, rising investment in biologic therapies, an expanding geriatric population, the broader reach of online pharmacy distribution, and advancements in monoclonal antibody treatments. Key trends expected during this time include the development of personalized therapies, the implementation of combination drug regimens, a focus on bone health management in multiple myeloma, the evolution of targeted drug delivery systems, and the expansion of clinical trials.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11943&type=smp

Which Drivers Are Expected To Impact The Multiple Myeloma Drugs Market During The Forecast Period?

The rising occurrence of hematological cancer is projected to propel expansion within the multiple myeloma drugs market in the future. These cancers originate in blood-forming tissues like bone marrow, or in immune system cells, encompassing conditions such as leukemia, lymphoma, and multiple myeloma, among others. Medications for multiple myeloma are frequently employed to manage diverse myeloma types by eradicating and hindering the proliferation of cancer cells. This is achieved through reducing cell division processes via stimulating various enzymatic activities, while also helping maintain bone strength and alleviating discomfort in compromised bones. As an illustration, in January 2023, the American Cancer Society (ACS), a US-based health body focused on eradicating cancer, reported approximately 59,610 new diagnoses of leukemia, with around 20,380 of these being acute myeloid leukemia (AML). Furthermore, the total fatalities attributed to leukemia reached 23,710. Consequently, the growing incidence of hematological cancer is fueling the expansion of the multiple myeloma drugs market.

Which Segments Are Driving Activity In The Multiple Myeloma Drugs Market?

The multiple myeloma drugs market covered in this report is segmented –

1) By Drug Type: Immunomodulatory Drugs, Proteasome Inhibitors, Histone Deacetylase Inhibitors, Monoclonal Antibody Drugs, Steroids, Other Drug Types

2) By Therapy: Targeted Therapy, Biologic Therapy, Chemotherapy, Other Therapies

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End-User: Men, Women

Subsegments:

1) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide

2) By Proteasome Inhibitors: Bortezomib, Carfilzomib, Ixazomib

3) By Histone Deacetylase Inhibitors: Panobinostat, Romidepsin

4) By Monoclonal Antibody Drugs: Daratumumab, Elotuzumab, Isatuximab

5) By Steroids: Dexamethasone, Prednisone

6) By Other Drug Types: Alkylating Agents, Antimetabolites, New Experimental Drugs

What Industry Trends Are Transforming The Multiple Myeloma Drugs Market?

Companies operating within the multiple myeloma drug market are reinforcing their collaborative approach to jointly develop cell therapies, expanding their partnerships to accelerate the development and commercialization of next-generation CAR T products. Strategic alliances facilitate shared resource utilization, risk reduction, and quicker scale-up for novel therapies. For instance, in May 2024, Kite Pharma, a US-based biopharmaceutical company, and Arcellx, Inc., a US-based clinical-stage biotechnology company, issued key operational updates for their partnered BCMA CAR T therapy, anitocabtagene autoleucel (anito cel). The companies revealed the design of a global Phase 3 trial, named iMMagine 3, which will evaluate anito cel in patients with relapsed or refractory multiple myeloma who have previously been treated with both an immunomodulatory drug (IMiD) and an anti-CD38 monoclonal antibody. This trial is anticipated to enroll approximately 450 patients globally.

Which Major Firms Are Strengthening Their Position In The Multiple Myeloma Drugs Market?

Major companies operating in the multiple myeloma drugs market are Pfizer Inc., Johnson & Johnson Pvt. Ltd, Merck & Co. Inc., AbbVie Inc., Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Kite Pharma Inc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Cipla Ltd., ONO Pharmaceutical Co. Ltd., BieGene Ltd., Onyx Pharmaceuticals Inc., Karyopharm Therapeutics Inc., Poseida Therapeutics Inc., ImmunoGen Inc., PharmaMar SA

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-drugs-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Multiple Myeloma Drugs Market?

North America was the largest region in the multiple myeloma drugs market in 2025. The regions covered in the multiple myeloma drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Multiple Myeloma Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11943&type=smp

Browse Through More Reports Similar to the Global Multiple Myeloma Drugs Market 2026, By The Business Research Company

Multiple Myeloma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-drugs-global-market-report

Multiple Myeloma Market Report 2026

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-global-market-report

Myeloproliferative Disorders Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795